Optimizing Glycemic Control in Type 2 Diabetes with Cost Constraints

Target Glycemic Control

The American College of Physicians recommends targeting an A1C between 7-8% for most adults with type 2 diabetes, as this represents the evidence-based goal 1, 2, 3
The American College of Physicians acknowledges that sulfonylureas and long-acting insulins are inferior to SGLT-2 inhibitors and GLP-1 agonists in reducing all-cause mortality and morbidity, but may still have some limited value for glycemic control 1

Glipizide can lower A1C by approximately 0.7-1.0% per dose increase, making it a viable option for optimizing glycemic control 5
If A1C remains above 8% after maximizing glipizide, adding basal insulin (NPH or long-acting analog) is recommended, starting with NPH insulin 10 units at bedtime or 0.1-0.2 units/kg/day of long-acting insulin analog 3, 5
When adding insulin, reducing glipizide dose by 50% immediately is recommended to prevent severe hypoglycemia, especially given the fluoxetine interaction 1

The American College of Physicians strongly recommends against adding a DPP-4 inhibitor due to lack of mortality benefit (strong recommendation, high-certainty evidence) 2, 6
Do not delay treatment intensification, as therapeutic inertia worsens outcomes 3
Do not target A1C below 6.5%, as this requires treatment deintensification to avoid hypoglycemia 1, 2

When the patient can afford newer agents, immediately adding an SGLT-2 inhibitor or GLP-1 agonist and reducing or discontinuing glipizide is recommended, as these agents reduce all-cause mortality and major adverse cardiovascular events with high-certainty evidence 1, 2, 6, 9, 10